Diagnosis and Management of Multiple Sclerosis: Case Studies

Neurologic Clinics

Volumn 24, Issue 2, 2006, Pages 199-214

  Woo, Douglas A ^a   Olek, Michael J ^a   Frohman, Elliot M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; BETA1A INTERFERON; CORTICOSTEROID; MODAFINIL;

ADULT; CASE REPORT; FATIGUE; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SPASTICITY; SYMPTOM;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTI-INFLAMMATORY AGENTS; BRAIN; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FEMALE; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OPTIC NEURITIS;

EID: 33646197077     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2006.01.002     Document Type: Review

References (34)

1. McDonald W.I., Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Aclerosis. Ann Neurol 50 (2001) 121-127
2. Beck R.W., Trobe J.D., Moke P.S., et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis. Arch Ophthalmol 121 (2003) 944-949
3. Tintore M., Rovira A., Brieva L., et al. Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and different MR imaging criteria to predict conversion to CDMS. Mult Scler 7 (2001) 359-363
4. Sastre-Garriga J., Tintore M., Rovira A., et al. Conversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fluid and neurophysiological findings. Mult Scler 9 (2003) 39-43
5. Barkhof F., Filippi M., Miller D.H., et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120 Pt 11 (1997) 2059-2069
6. Frohman E.M., Goodin D.S., Calabresi P.A., et al. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 61 (2003) 602-611
7. Jacobs L.D., Beck R.W., Simon J.H., et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343 (2000) 898-904
8. Comi G., Filippi M., Barkhof F., et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357 (2001) 1576-1582
9. Ruggieri R.M., Settipani N., Viviano L., et al. Long-term interferon-beta treatment for multiple sclerosis. Neurol Sci 24 (2003) 361-364
10. Mohr D.C., Goodkin D.E., Masuoka L., et al. Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis. Mult Scler 5 (1999) 192-197
11. Frohman E.M., Brannon K., Alexander S., et al. Disease modifying agent related skin reactions in multiple sclerosis: prevention, assessment, and management. Mult Scler 10 (2004) 302-307
12. Frohmann E., Phillips T., Kokel K., et al. Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. Neurologist 8 (2002) 227-236
13. Sorensen P.S., Koch-Henriksen N., Ross C., et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 65 (2005) 33-39
14. Francis G.S., Rice G.P.A., Alsop J.C., and PRISMS Study Group. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 65 (2005) 48-55
15. Kappos L., Clanet M., Sandberg-Wollheim M., et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 65 (2005) 40-47
16. Zivadinov R., Rudick R.A., De Masi R., et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 57 (2001) 1239-1247
17. Morrow S.A., Stoian C.A., Dmitrovic J., et al. The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology 63 (2004) 1079-1080
18. Metz L.M., Sabuda D., Hilsden R.J., et al. Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis. Neurology 53 (1999) 2093-2096
19. Barnes D., Hughes R.A.C., Morris R.W., et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 349 (1997) 902-906
20. Sharrack B., Hughes R.A.C., Morris R.W., et al. The effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in multiple sclerosis. J Neurol Sci 173 (2000) 73-77
21. Zorzon M., Zivadinov R., Locatelli L., et al. Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. Eur J Neurol 12 (2005) 550-556
22. Reggio E., Nicoletti A., Fiorilla T., et al. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients. Twenty-four months follow-up. J Neurol 252 (2005) 1255-1261
23. Smith D. Preliminary analysis of a trial of pulse cyclophosphamide in IFN-beta-resistant active MS. J Neurol Sci 223 (2004) 73-79
24. Weiner H.L., and Cohen J.A. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler 8 (2002) 142-154
25. Cavazzuti M., Merelli E., Tassone G., et al. Lesion load quantification in serial MR of early relapsing multiple sclerosis patients in azathioprine treatment. A retrospective study. Eur Neurol 38 (1997) 284-290
26. Lus G., Romano F., Scuotto A., et al. Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment. Eur Neurol 51 (2004) 15-20
27. Calabresi P.A., Wilterdink J.L., Rogg J.M., et al. An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology 58 (2002) 314-317
28. Goodin D.S., Anason B.G., Coyle P.K., et al. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 61 (2003) 1332-1338
29. Likosky W.H., Fireman B., Elmore R., et al. Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiatry 54 (1991) 1055-1060
30. The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 337 (1991) 441-446
31. Hohol M.J., Olek M.J., Orave E.J., et al. Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease. Mult Scler 5 (1999) 403-409
32. Weiner H.L., Mackin G.A., Orave E.J., et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 43 (1993) 910-918
33. Zephir H., de Seze J., Duhardin K., et al. One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis. Mult Scler 11 (2005) 360-363
34. Hommes O.R., Sorensen P.S., Fazekas F., et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 364 (2004) 1149-1156